Need an expert perspective on cancer science, policy, or patient care? ASCO experts are knowledgeable on a wide variety of cancer topics. Expert Connect showcases a selection of the experts ASCO has available for media interviews. If you’d like to interview one of the experts below, or you’re uncertain about who you’d like to speak with, please email email@example.com, and we will do our best to connect you with the appropriate expert.
Disclosures for the experts listed below can be referenced here.
Dr. Bertagnolli is a professor of surgery at Harvard Medical School, and chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.
Since joining ASCO in 1995, Dr. Bertagnolli has served on the Board of Directors (2007-2011), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.
In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.
Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.
View current ASCO disclosure here.
Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.
Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.
Dr. Burris served as the elected president of ASCO in 2019-2020. He currently serves as the Chair of the Society's Board and also as the Chair of the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.
Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.
View current ASCO disclosure here.
Bruce E. Johnson, MD, FASCO, is Chief Clinical Research Officer and Institute Physician at the Dana-Farber Cancer Institute and a Professor of Medicine at Harvard Medical School. He is the Director of the Dana-Farber/Harvard Cancer Center (DF/HCC) Lung Cancer Program. He stepped down as the Director of the Lowe Center for Thoracic Oncology, a position he held beginning in 1998 through 2013.
An ASCO member since 1985, Dr. Johnson has served in numerous volunteer and leadership roles, including the Board of Directors (2008-2011), Chair of the Audit, Cancer Education, and Cancer Communications Committees, and on the Journal of Clinical Oncology Editorial Board, among other positions. In 2008, he was award the Translational Research Professorship from the Conquer Cancer Foundation of ASCO.
Dr. Johnson has been active on committees and study sections within the National Cancer Institute, including recent service on the Special Emphasis Panel to review SPOREs, the Clinical Oncology Study Section, and on the Thoracic Malignancy Steering Committee, among others. He has served on a number of external advisory boards, including the External Advisory Committee for The Cancer Genome Atlas. He is a member of the Scientific Advisory Board for The University of Texas MD Anderson Moon Shots Program, and is active in the American Association for Cancer Research (AACR) and the International Association for the Study of Lung Cancer (IASLC), as well as other professional organizations. He was awarded the IASLC Scientific Award in 2009. In 2010, he was one of the leaders of the team honored with the AACR Team Science Award. He was elected to the Association of American Physicians in 2015.
Dr. Johnson earned his undergraduate degree from Harvard University and his medical degree from the University of Minnesota. He completed his internship and residency in internal medicine at the University of Chicago Hospitals and Clinics. He concluded his training as a Clinical Associate at the National Cancer Institute.
View current ASCO disclosure here.
Dr. Hudis is the Chief Executive Officer of the American Society of Clinical Oncology (ASCO). He also serves as the Executive Vice Chair of its Conquer Cancer Foundation and Chair of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of volunteer and leadership roles at ASCO, including as its President during the Society’s 50th anniversary year (2013-14). Before coming to ASCO full-time, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City and Professor of Medicine at the Weill Medical College of Cornell University. As CEO of ASCO, Dr. Hudis is responsible for delivering on the board’s strategic goals through education, research, and support for the delivery of the highest quality of care by the Society’s nearly 45,000 members.
Read Dr. Hudis’ Q&A on ASCO Connection.
View current ASCO disclosure here.
Dr. Schilsky is the Chief Medical Officer (CMO) and Executive Vice President of ASCO. Formerly the Chief of Hematology/Oncology in the Department of Medicine and Deputy Director of the University of Chicago Comprehensive Cancer Center, he is a highly respected leader in the field of clinical oncology. He specializes in new drug development and treatment of gastrointestinal cancers. Dr. Schilsky is a Past President of ASCO, having served in the role during 2008-2009, and is also a Past Chair of one of the National Cancer Institute’s Cooperative Groups, Cancer and Leukemia Group B (CALGB).
Dr. Schilsky’s impressive experience and many accomplishments in both clinical medicine and clinical research reflect his deep passion for cancer medicine. He has spent the majority of his career at the University of Chicago, where he joined the faculty in 1984, subsequently rising to the rank of Professor of Medicine and serving in many roles, including Associate Dean for Clinical Research in the Biological Sciences Division and Director of the University of Chicago Cancer Research Center.
From 1995 to 2010, Dr. Schilsky served as Chair of the Cancer and Leukemia Group B (CALGB), a national cooperative clinical research group funded by the National Cancer Institute (NCI). He has extensive experience working with both the NCI and the Food and Drug Administration (FDA) having served as a member and chair of the NCI Board of Scientific Advisors, as a member of the NCI Clinical and Translational Research Committee, and as a member and chair of the Oncologic Drugs Advisory Committee of the FDA. Dr. Schilsky has served on the editorial boards of many cancer journals, including the Journal of Clinical Oncology. He presently serves on the editorial board of the New England Journal of Medicine.
Early in his career, he worked in the Clinical Pharmacology Branch of the Division of Cancer Treatment at the NCI and was an Assistant Professor in the Department of Internal Medicine, Division of Hematology and Oncology at the University of Missouri-Columbia School of Medicine. He was also the head of the hematology/medical oncology unit at the Harry S. Truman Veterans’ Administration Hospital in Columbia, Missouri.
Sumanta (Monty) Kumar Pal, MD, is an internationally recognized leader in the area of genitourinary cancers, including kidney, bladder, and prostate cancer. He is the Co-director of City of Hope's Kidney Cancer Program and is the head of the kidney and bladder cancer disease team at the institution.
Dr. Pal entered college at the age of 13 and began medical school at University of California, Los Angeles at the age of 17. After completing his residency training at University of California, Los Angeles, Dr. Pal completed a fellowship program in medical oncology at City of Hope's comprehensive cancer center where he remains on faculty since 2009.
Over that span of time, he has published more than 200 peer-reviewed articles that have been featured in prominent journals including The Journal of Clinical Oncology, Lancet Oncology, Cancer Cell, and European Urology.
Dr. Pal holds patents for new drugs currently under development in prostate cancer and also maintains one of the largest portfolios of clinical trials for kidney and bladder cancer research on the west coast. He developed an integrated program that focuses heavily on collaborations with basic science researchers at Beckman Research Institute of City of Hope and urologists in the Department of Surgery. Ultimately, Dr. Pal’s goal is to stimulate collaborative research across multiple departments in order to discover novel therapeutic approaches for our currently incurable diseases. He has also worked to push the boundaries of personalized medicine in genitourinary cancers, with several seminal publications in rare genitourinary cancers that describe unique therapeutic targets.
Dr. Pal sits on the Editorial Board for Clinical Genitourinary Cancer and Kidney Cancer and is a reviewer for multiple journals including The Journal of Clinical Oncology, The Journal of Urology, European Urology, and many others. Dr. Pal has received grants from the National Institute of Health, the Comprehensive Cancer Network, SWOG, and multiple other leading entities in support of his formidable research.
John V. Heymach, MD, PhD, is the Chair of Thoracic/Head and Neck Medical Oncology and a Professor in the Departments of Thoracic Head and Neck Medical Oncology and Cancer Biology at The University of Texas MD Anderson Cancer Center. Dr. Heymach joined the faculty in 2005 as an Assistant Professor, with a joint appointment in Thoracic/Head and Neck Medical Oncology and Cancer Biology. He was promoted to Associate Professor in 2009 and Professor in 2013. He received his undergraduate degree from Harvard University and both his MD and PhD from Stanford University Medical School in California. He then completed his Internship and Residency at Brigham and Women’s Hospital and his fellowship in Medical Oncology at Dana Farber Hospital. During his fellowship, he worked in the laboratory of Dr. Judah Folkman with clinical mentorship under Dr. Bruce Johnson.
As a physician-scientist, his research focuses on investigating mechanisms of therapeutic resistance to targeted agents, understanding the regulation of angiogenesis in lung cancer, and the development of biomarkers for selecting patients most likely to benefit from targeted agents. He has led a number of Phase I/II clinical trials testing novel targeted therapies in NSCLC.
Dr. Heymach serves as a Project Co-Leader on the UT Lung Cancer SPORE and is the PI on three NCI R01 awards, a V Foundation Translational Research Award, a CPRIT Multi-Investigator Award Project, and is the site leader on a SU2C award. He also serves as leader of the Lung Cancer Program of the Cancer Center Support Grant and co-leads the MD Anderson Lung Cancer Moon Shot Program. He is a past recipient of the Damon Runyon Clinical Investigator Award, an ASCO Career Development Award, the Wilson Stone Award for Basic Science Research, and the Emil J. Frei Award for Translational Research. He was elected to the American Society for Clinical Investigation in 2013.
Brian M. Alexander, MD, MPH, is the disease center leader for radiation oncology at the Center for Neuro-Oncology at the Dana-Farber Cancer Institute, as well as an assistant professor of radiation oncology at Harvard Medical School. He attended medical school at the University of Michigan, completed his internship at Saint Joseph Mercy Hospital in Ann Arbor, Michigan, and completed his residency in the Harvard Radiation Oncology Program. Dr. Alexander’s clinical and research interests include tumors of the central nervous system.
Dr. Nancy Baxter obtained her MD and PhD in Clinical Epidemiology from University of Toronto (UofT). She is board certified in colon and rectal surgery and a Fellow of the ASCRS. Currently, she is the Head of the Division of General Surgery at St. Michael’s Hospital. She holds a Scientist position with the Li Ka Shing Knowledge Institute and is a Senior Scientist at the Institute for Clinical Evaluative Sciences (ICES).
Dr. Baxter is the Associate Dean of Academic Affairs at the Dalla Lana School of Public Health and a Professor in the Department of Surgery and Institute of Health Policy, Management and Evaluation at the UofT. She holds the position of Provincial GI Endoscopy lead for Cancer Care Ontario.
She is a clinical epidemiologist and health services researcher interested in the effectiveness of cancer screening, long-term cancer survivorship of cancer, and the quality of surgical care. She has extensive experience in the use of administrative data and cancer registry data to evaluate long-term consequences of cancer care for adults.
Harold J. Burstein, MD, PhD, is an Associate Professor of Medicine at Harvard Medical School, and a medical oncologist at Dana-Farber Cancer Institute and Brigham & Women's Hospital. Dr. Burstein attended Harvard College, and earned his MD at Harvard Medical School where he also earned a PhD in immunology. He additionally has a master's degree in history of science from Harvard. He trained in internal medicine at Massachusetts General Hospital and in medical oncology at Dana-Farber.
His clinical research interests include novel treatments for early- and advanced-stage breast cancer, and studies of quality of life and health behavior among women with breast cancer. Dr. Burstein has written widely on breast cancer in both traditional medical journals and on the web. Representative publications can be found in the New England Journal of Medicine, the Journal of Clinical Oncology, and other leading medical journals. He serves on international breast cancer committees including the NCCN Breast Cancer Panel, The St. Gallen Breast Cancer Panel, and the Alliance Breast Cancer Committee, and chairs the ASCO guidelines on endocrine therapy for breast cancer. Dr. Burstein is an Associate Editor for Cancer Education at the Journal of Clinical Oncology.
William Dale, MD, PhD is an internist, geriatrician, and supportive care physician and a health services researcher who has devoted his career to the care of older adults with cancer. As Chair of the Department of Supportive Care Medicine at City of Hope, Dr. Dale is committed to providing comprehensive, multidisciplinary, integrated care that is evidence-based for patients across the lifespan.
Dr. Dale has well over 120 publications on a variety of topics including medical decision making, behavioral economics, quality of life assessment, and frailty evaluation in older adults, especially in those with cancer. His research has particularly advanced our understanding of care management, shared decision making, and care models for older adults with cancer. He has been continuously funded by the NIH (NIA, NCI), PCORI, American Cancer Society, John A. Hartford Foundation and philanthropy throughout his academic career.
Don S. Dizon, MD, FACP, FASCO is the Head of Women’s Cancers at Lifespan Cancer Institute, Director of Medical Oncology at Rhode Island Hospital, and Associate Professor of Medicine at The Warren Alpert Medical School of Brown University in Providence, RI (USA). He was trained in medical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) where he was also on the faculty in the Developmental Therapeutics section and Gynecologic Oncology Disease Management Team at MSKCC until 2003. Between 2003 and 2009 he was the director of medical oncology at the Program in Women's Oncology at Women & Infants Hospital of Rhode Island where he also founded the Center for Sexuality, Intimacy, and Fertility for women with cancer (CSIF)- the first program of its kind in Rhode Island. In July 2012, he transferred his clinical practice to MGH, where he founded and directed the Oncology Sexual Health Clinic at the MGH Cancer Center. Between 2014 and 2017 he was the Clinical Co-Director of Gynecologic Oncology at the MGH Cancer Center. In addition to his clinical duties, he is a co-chair of the Cervical Cancer Task Force for the NCI Gynecologic Cancer Steering Committee, section editor in Gynecologic Oncology at UpToDate, and serves on multiple editorial boards, including for The Oncologist, the Journal of Clinical Oncology, and the American Journal of Clinical Oncology. He is also prolific on social media and maintains online columns at Connecton and for the journal, The Oncologist. He chairs the Digital Engagement Committee for SWOG, a member of the NCI National Clinical Trials Network. In 2018, he was named a Fellow of the American Society of Clinical Oncology.
Dr. Dizon is on Instagram and on Twitter as @drdonsdizon.
Robert Dreicer, MD, MS, MACP, FASCO is the Associate Director for Clinical Research and the Deputy Director of the University of Virginia Cancer Center. He serves as Section Head of Medical Oncology and Co-Director of the Paul Mellon Urologic Institute. He is a Professor of Medicine and Urology at the University of Virginia School of Medicine. He previously served as Chair of the Department of Solid Tumor Oncology at the Cleveland Clinic and Deputy Associate Director for Clinical Research for the Case Comprehensive Cancer Center. Dr. Dreicer is board certified in internal medicine and medical oncology. His areas of specialization are the management of genitourinary malignancies and the design and conduct of clinical trials in urologic oncology. Dr. Dreicer received his BS degree at Colorado State University and his MS degree at the University of Texas Graduate School of Biomedical Sciences in Houston, TX. He received his MD from the University of Texas Medical School at Houston. He completed an internal medicine residency at Indiana University in Indianapolis, followed by a medical oncology fellowship at the University of Wisconsin Carbone Clinical Cancer Center in Madison, Wisconsin. Dr. Dreicer has published widely in genitourinary oncology, and served as principle investigator of a large number of studies in genitourinary neoplasms. From 2012-18 he served as Co-Chair of the NCI GU Steering Committee. He is a member of the editorial board of New England Journal of Medicine’s Journal Watch Hematology/Oncology, as well as Lancet Oncology’s International Advisory Board. In October of 2016 he was awarded Mastership in the American College of Physicians.
Andrew S. Epstein, MD, is an Assistant Attending Physician and Assistant Member at Memorial Sloan Kettering Cancer Center. He earned his medical degree at Loyola University of Chicago Stritch School of Medicine and completed his residency at New York’s Mount Sinai Hospital, where he was later a Palliative Medicine fellow. He completed medical oncology fellowship at Memorial Sloan Kettering Cancer Center, where he holds joint Department of Medicine service appointments in GI Medical Oncology and Palliative Medicine (Supportive Care).
Clinically, Dr. Epstein cares primarily for patients with colorectal, pancreas, biliary, esophagogastric, and other gastrointestinal cancers.
His research focuses on improving the delivery of care to patients and their families by optimally integrating cancer care with palliative medicine, with the goal of reducing distress and maximizing quality living for people with cancer. He has received grant funding for research in patient–physician communication and advance care planning from various organizations including from ASCO (2010 Young Investigator Award), the National Palliative Care Research Center (2013 Career Development Award), and the Cambia Health Foundation (2017 Sojourns Scholar Leadership Program Award). In collaboration with the Department of Psychiatry and Behavioral Sciences, he also teaches communication skills to medical oncology fellows at Memorial Sloan Kettering Cancer Center.
In addition, Dr. Epstein serves as a reviewer for various oncology publications including The Journal of Clinical Oncology, The Journal of Oncology Practice, JAMA Oncology, and Annals of Oncology.
Finally, Dr. Epstein serves as a member on the New York State Cancer Consortium Palliative Care Program Committee and the Steering Committee of What Matters: Caring Conversations About End of Life.
Originally published in the 2008 ASCO Daily News
In her 30 years as an oncologist, Patricia A. Ganz, MD, has seen the evolution of cancer treatments progress from extreme radical surgical procedures to organ-sparing operations. She has witnessed the growth of the general understanding of the biology of cancer, an increasing trend of early diagnosis, and the identification of the molecular switches that control the initiation and promotion of cancer. She also remembers a time when people with cancer were low on the list of an oncologist’s priorities.
“In the late 1980s and early 1990s, it was not very popular to suggest that we include the patient’s voice in assessing the outcomes of treatment,” Dr. Ganz told ASCO Daily News. “Collecting quality-of-life data within clinical trials was viewed as burdensome.”
Quality-of-life and quality-of-care issues have come a long way in oncology, and Dr. Ganz has been a major force behind that progress. Her dedication to the prevention, detection, and treatment of cancer and to caring for the whole patient has contributed greatly to the expansion of oncology’s scope in recent years. For her achievements and professional leadership, ASCO is presenting Dr. Ganz with the 2008 ASCO/American Cancer Society Award. The award is designed to recognize individuals who have made significant contributions to the prevention and management of cancer. Dr. Ganz will accept the award and deliver her lecture, “Improving Outcomes of Cancer Survivors: Lessons Learned from the Treatment of Breast Cancer,” today from 11:30 AM–12:30 PM in the South Building, Room S404.
Before and After Cancer: Prevention and Survivorship
Dr. Ganz’s career in oncology began with a focus on patient issues. In 1973, she graduated with a medical degree from the University of California, Los Angeles (UCLA) School of Medicine and began her post-doctoral training in internal medicine and medical oncology at the UCLA Medical Center. Dr. Ganz notes that the study of cancer was in a transitional phase at that time. Adjuvant therapy for the disease was experimental but was demonstrating promise in prolonging survival. Except for Pap smears, there were no routine screening tests available for cancer. Most patients were diagnosed in the advanced stages of disease and, despite surgery and radiation therapy, recurrences were common. The hospice movement, focusing on pain and symptom management, was becoming increasingly influential. This movement was a part of Dr. Ganz’s first encounters with the incorporation of quality of life into the management of cancer.
“When I took my first faculty position after completing my fellowship training, I had the opportunity to start a palliative care unit for cancer patients. I decided that we should not wait until someone was in the last weeks of life to apply all of the supports of hospice, so we focused on physical rehabilitation, pain and symptom control, and psychosocial support from the time of diagnosis until death,” Dr. Ganz said. “Many patients in my practice had advanced disease and eventually succumbed, but some of my patients became long-term survivors, even then.”
Since that time, the field of oncology has shifted its focus and has acknowledged the significance of the experience that a patient has from the initial diagnosis through treatment and, increasingly, to survivorship. Researchers and clinicians not only seek to understand the biology of the disease and its treatments but also focus increasingly on the before and after of cancer: prevention and survivorship.
Current Research Regarding Quality-of-life Outcomes
Dr. Ganz has devoted her career to these aspects of oncology. Today, she is the Director of the Division of Cancer Prevention and Control Research of the Jonsson Comprehensive Cancer Center at UCLA, and leads a large research group that applies the scientific disciplines of public health to research on the prevention, detection, treatment, and supportive care of cancer. She is also Professor of Medicine at the David Geffen School of Medicine at UCLA and Professor of Health Services at the UCLA School of Public Health. Some of her recent research has investigated the significant effects that quality-of-life outcomes can have throughout the treatment of patients with cancer.
“After telling someone ‘you have cancer,’ they often shut down and don’t hear another word the physician says,” said Dr. Ganz, who currently Chairs the Behavioral and Health Outcomes Committee for the National Surgical Adjuvant Breast and Bowel Project (NSABP), an NCI-funded cooperative group. “The diagnosis can be extremely stressful even for those with the best coping skills.”
She noted that to the extent possible, the NSABP now routinely incorporates patient-reported outcomes in relevant treatment and prevention trials to enhance the interpretation of the biomedical findings.
“In leading the quality-of-life studies for the Breast Cancer Prevention Trial [BCPT] and the Study of Tamoxifen and Raloxifene [STAR], I was able to demonstrate the added value of patient-reported outcomes in the clinical trial setting,” Dr. Ganz said.
Stress can be compounded, she added, when patients must confront other issues surrounding their diagnosis, such as the lack of social support, poor or no health insurance, language barriers, or pre-existing medical or psychologic problems. As the patient moves through the treatment process, the issues they face often alter drastically.
Dr. Ganz’s research has explored the unique requirements and challenges in treating patients in all stages of cancer, including those who have survived it. For 20 years, she has led an active research program dedicated to investigating the effect of cancer treatment on the long-term health and well-being of breast cancer survivors. She was named a Susan G. Komen Breast Cancer Foundation Professor of Survivorship in 1999. In 2004, she served as Co-Chair of ASCO’s Survivorship Task Force. In 2006, she was awarded funding to lead UCLA’s Cancer Survivorship Center of Excellence as part of the LIVESTRONGTM Survivorship Center of Excellence Network. Today, after having served on the Institute of Medicine committee that prepared the 2005 report From Cancer Patient to Cancer Survivor: Lost in Transition, she continues to promote awareness in the medical community of the importance of improving the coordination of care for cancer survivors, including symptom management and supportive care.
“There will soon be 12 million cancer survivors and growing, and this is a target population for clinical trials as well as clinical care,” she said. “We need to learn from the outcomes of cancer survivors in order to appropriately modify our treatment strategies, as well as coordinate their post-treatment follow-up care.”
Ongoing Challenges for Cancer Survivors
Dr. Ganz emphasized that many cancer survivors require a unique kind of care from their oncologists. She noted that as a patient moves through treatment and into the survivorship stage, their needs shift as the chance for recurrence diminishes. Survivors may face ongoing symptoms or problems resulting from their initial treatments — pain, fatigue, menopausal symptoms — and be at risk for late effects, such as second cancers or organ dysfunction, as well as other chronic diseases.
“Oncologists do a good job with the cancer surveillance portion of care, but rarely address prevention, adequate management of symptoms (especially psychosocial needs), and health promotion. This is where survivorship care comes in,” she said. “Sharing the care of the patient with a primary care physician can ensure that symptom management, prevention, and health promotion are addressed.”
Dr. Ganz also has been an active advocate of the improvement of the cancer care that is delivered to all patients. She is the current Chair of ASCO’s Quality Cancer Care Committee and Co-Chair of the Cancer Quality Alliance, helping ASCO and other organizations develop and promote the measurement of quality care performance in clinical practice. In her research and professional activities, she is a leader in the promotion of the regular integration of evidence-based practices into everyday treatment.
“In oncology, we have far more evidence about what works and doesn’t work than many other aspects of clinical medicine. What we have learned from cancer clinical trials is not always put into practice,” said Dr. Ganz. “It is surprising how few physicians follow recommended treatment strategies, such as ASCO Guidelines.”
History of ASCO Service
An ASCO member since 1980, Dr. Ganz has volunteered in a variety of capacities for the Society, serving as a member of the Cancer Education Committee, the Scientific Program Committee, the Personnel Committee, the Cancer Prevention Committee, and the Strategic Planning Committee. From 2003 to 2006, she was a member of the Board of Directors, serving on the Executive Committee from 2005 to 2006. She also is an Editor for the Journal of Clinical Oncology and serves as a specialty editor for Clinical Cancer Advances. Recently, she also was the Chair of the Electronic Health Records Workgroup. For her lengthy record of service, the Society is presenting Dr. Ganz with a 2008 ASCO Statesman Award.
Dr. Ganz has been honored many times throughout her career with prestigious awards recognizing her leadership and dedication to oncology. In 1999, she was named an American Cancer Society Professor of Clinical Research. The Breast Cancer Research Foundation awarded her the Jill Rose Award for Breast Cancer Research in 2005 and she received the American Society of Breast Disease’s Pathfinder Award in 2006. In 2007, the American Cancer Society honored Dr. Ganz again with its Distinguished Service Award; also in 2007, Dr. Ganz was elected to membership in the Institute of Medicine.
After learning of her selection as the winner of the ASCO/American Cancer Society Award, she was “very honored to be nominated and selected by my colleagues.” She will focus her lecture on the lessons that she has learned from her work with breast cancer survivors.
“With the growing numbers of cancer survivors, members of ASCO need to be thinking about survivorship outcomes from the beginning of cancer treatment, including choice of treatments and the risks/benefits of late effects,” she said. “I am hopeful that we will see a continued decline in the incidence of cancer in the coming decades so that we less often have to say ‘I’m sorry, you have cancer.’”
Dr. Timothy Gilligan is a medical oncologist, Vice-Chair for Education, and Associate Professor of Medicine at the Cleveland Clinic Taussig Cancer Institute. He specializes in cancers of the testicles, kidneys, prostate and bladder. Dr. Gilligan is Director of Coaching at the Cleveland Clinic Center for Excellence in Healthcare Communication, and co-editor of the book Communication the Cleveland Clinic Way. At Cleveland Clinic and other hospitals and at national and international conferences, he teaches communication skills, team-building, and coaching, and trains others to teach communication skills. Dr. Gilligan works on quality of care and clinical practice guidelines with the American Society of Clinical Oncology (ASCO) and the National Cancer Institute, and chairs the testis cancer panel for the National Comprehensive Cancer Network (NCCN). He helps teach the ASCO Quality Training Program and co-chairs the ASCO panel writing guidelines on patient-physician communication. He speaks regularly at national oncology meetings and board review courses and urological cancers and healthcare communication.
Dr. Gilligan graduated from Stanford University School of Medicine and Columbia University Graduate School of Journalism. He trained in internal medicine and medical oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute. He completed the American Academy on Communication in Healthcare three-year faculty training program and is a member of their faculty. He also completed the OncoTalk Teach program.
David Graham, MD, FASCO obtained his medical degree at Mayo Medical School in 1987. He trained in Internal Medicine, Hematology, and Oncology at the Mayo Graduate School of Medicine. He was a Clinical Assistant Professor at the University of Illinois at Urbana/Champaign School of Medicine from 1993-2013. He is now a Medical Director at Levine Cancer Institute in Charlotte, NC. His clinical interests focus in genitourinary cancers as well as the impact that social media and other technologies can have on patient care. He is an Associate Editor for ASCO eLearning and serves on the Social Media Working Group for ASCO.
Daniel F. Hayes, MD, FACP, FASCO, is a Professor of Internal Medicine, the Stuart B. Padnos Professor in Breast Cancer, and the Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center. He is a breast cancer specialist.
An ASCO member since 1986, Dr. Hayes has served the Society in numerous volunteer capacities. In addition to serving as Immediate Past President, he is involved in several ASCO Expert Panels related to breast cancer, including the ASCO-College of American Pathologists Estrogen Receptor/Progesterone Receptor and the HER2 Testing Panels (Co-Chair), the Breast Cancer Consensus Panel, Use of Tumor Biomarkers in Advanced Breast Cancer and Early-Stage Breast Cancer Panels, and the Breast Cancer Guideline Advisory Group, among others. He served on the ASCO Board of Directors from 2011-2014, on the Conquer Cancer Foundation Grants Selection Committee, as Chair of the Scientific Program Committee, and on the Journal of Clinical Oncology Editorial Board. In 2007, he was presented with ASCO’s Gianni Bonadonna Breast Cancer Award and Lecture; in 2013, he was elected as a Fellow of ASCO (FASCO).
Dr. Hayes is past Chair of the Breast Cancer Intergroup of North America’s Correlative Sciences Committee and Chair of the Southwest Oncology Group’s Breast Cancer Translational Medicine Committee. He is a member of the Union for International Cancer Control (UICC) TNM Expert Advisory Panel on Breast Tumours and the Early Breast Cancer Clinical Trials Collaborative Group (the Oxford Overview) Executive Committee. He serves on the Susan G. Komen for the Cure Scientific Advisory Council as a Komen Scholar, in addition to several other past and current leadership roles.
Dr. Hayes completed his undergraduate degree and master’s degree in biochemistry at Indiana University and obtained his medical degree from Indiana University School of Medicine. He completed his internship and residency at Parkland Memorial Hospital/University of Texas Southwestern Medical School and a medical oncology fellowship at Harvard Medical School’s Dana-Farber Cancer Institute.
Stephen P. Hunger, MD, is the Chief of the Division of Oncology, the Director of the Center for Childhood Cancer Research and the Jeffrey E. Perelman Distinguished Chair in the Department of Pediatrics, Children's Hospital of Philadelphia, and a Professor of Pediatrics at the Perelman School of Medicine at the University of Pennsylvania.
Dr. Hunger specializes in research and treatment regarding children, adolescents and young adults with acute lymphoblastic leukemia (ALL). He has authored more than 240 peer-reviewed manuscripts, almost all on pediatric ALL. He was the Vice-Chairman (2002-2007) and Chairman (2008-2015) of the Children’s Oncology Group (COG) ALL Disease Committee. In these roles he has been responsible for oversight of the design and conduct of clinical trials and linked translational research studies that enroll over 2000 children with ALL each year, including more than 70% of US children and adolescents diagnosed with ALL. Dr. Hunger leads the COG ALL TARGET Project, that has conducted comprehensive studies of the genetic features of childhood ALL and revolutionized understanding of the genomic landscape of pediatric ALL. These findings are now being translated to clinical trials of targeted therapy in Philadelphia chromosome-like ALL. Dr. Hunger is currently the Chairman of the SIOP Scientific Committee and also has a major interest in global oncology with a focus on improving cure rates for children with ALL in low and middle income countries.
Dr. Jones is a radiation oncologist and palliative care physician with expertise in the use of palliative radiotherapy. He completed medical school at NYU Langone School of Medicine, internship and residency in Radiation Oncology at the Hospital of the University of Pennsylvania and fellowship in Palliative Medicine at the Massachusetts General Hospital/Harvard Palliative Medicine Fellowship. His clinical expertise is in the treatment of patients with advanced and metastatic cancer with a focus on the use of radiotherapy to improve symptom control and quality of life. He believes strongly in an interdisciplinary team approach to providing care for patients and families, focusing on the patient as a person in the context of his or her life and trying to return the patient to optimal functioning. His educational endeavors and research focus on the following areas:
- using radiotherapy to improve symptoms, quality of life and overall functioning in patients with advanced and metastatic cancer;
- optimizing symptom management in patients with advanced and metastatic cancer receiving radiotherapy.
- enhancing communication between providers and patients/families living with advanced and metastatic cancer.
Smitha S. Krishnamurthi, MD, obtained her medical degree at University of Pennsylvania School of Medicine, Philadelphia, PA in 1993. She completed her residency in Internal Medicine at Hospital of the University of Pennsylvania, followed by a fellowship at Johns Hopkins University, in Medical Oncology. Dr. Krishnamurthi is a medical oncologist and an Associate Professor of Medicine at University Hospitals Case Medical Center and Case Western Reserve University.
Dr. Krishnamurthi is the Director of the Clinical Trials Office for the Case Comprehensive Cancer Center as well as Lower Gastrointestinal Cancers Disease Team Leader. Her research interests include gastrointestinal cancers and developmental therapeutics. In 2013 Dr. Krishnamurthi was named a Department of Medicine Master Clinician Educator. She has been recognized in Cleveland Magazine’s Best Doctors list for 10 consecutive years.
Gary H. Lyman, MD, MPH, FACP, FRCP (Edin), FASCO, is Co-Director of the Hutchinson Institute for Cancer Outcomes Research, a Full Member of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, and a Professor of Medicine and Medical Oncology at the University of Washington.
In addition to serving on the ASCO Board of Directors, Dr. Lyman is a member of the Journal of Oncology Practice’s Editorial Board and Cancer Research Committee, as well as Chair of the Clinical Practice Guidelines Committee. He also sits on the Breast Cancer Consensus Panel, and is Co-Chair of the Breast Cancer Guideline Advisory and Survivorship Guideline Advisory Groups. An ASCO member since 1977, Dr. Lyman has served on the Journal of Clinical Oncology Editorial Board, the Cancer Education Committee, and as an Associate Editor of the Journal of Oncology Practice, among other activities.
Dr. Lyman has served as an advisor to the U.S. Food and Drug Administration’s Oncologic Drug Advisory Committee, and has been active in the Alliance for Clinical Trials in Oncology (formerly Cancer and Leukemia Group B), the Southwest Oncology Group, and the Eastern Cooperative Oncology Group. He has served on the Breast Cancer Screening and Diagnosis Panel and the Growth Factors Panel for the National Comprehensive Cancer Network, and as an editor for numerous academic journals.
Dr. Lyman received his medical degree from the State University of New York (Buffalo) and a Master of Public Health degree in Biostatistics from Harvard University School of Public Health. After completing a medical internship and residency at University of North Carolina, Chapel Hill, and a clinical medical oncology fellowship at Roswell Park Memorial Institute, he completed a postdoctoral fellowship at the Harvard University School of Public Health and the Dana-Farber Cancer Institute. He was Chief of Medicine at the Moffitt Cancer Center and Research Institute and Professor of Medicine at the University of South Florida and the University of Rochester before assuming his current positions at Duke University.
Gregory A. Masters, MD, FACP, FASCO, is an attending physician at the Helen F. Graham Cancer Center and serves as an Associate Professor at the Thomas Jefferson University Medical School. He earned his medical degree from Northwestern University, completed his residency at the University of Pennsylvania and finished his fellowship at the University of Chicago.
A lung cancer specialist, Dr. Masters also has interest in esophageal, gastrointestinal, head and neck cancers, thoracic oncology, and palliative care. He has served on the Thoracic Malignancies Steering Committee at the National Cancer Institute and works as a reviewer for several leading clinical oncology publications including Lancet, Journal of Clinical Oncology, Journal of Thoracic Oncology, Lung Cancer, Cancer, Clinical Lung Cancer, British Journal of Cancer and American Journal of Clinical Oncology.
Dr. Masters is the recipient of several awards and honors including the Fellow of the American Society for Clinical Oncology (FASCO), the ASCO Merit Award and the Christiana Care Health Services Physician Ambassador for Medical Oncology. He also serves as the Director of the Medical Oncology Fellowship for the Helen F. Graham Cancer Center and on the ASCO Cancer Communications Committee. As a published expert, he has traveled widely to speak on advancements in the treatment of Lung Cancer.
Erica L. Mayer, MD, MPH, is a Senior Physician and a breast cancer medical oncologist at the Susan F. Smith Center for Women’s Cancers/Dana-Farber Cancer Institute, as well as an Assistant Professor in Medicine at Harvard Medical School.
Dr. Mayer received her medical degree from Harvard Medical School in 2000. She completed a residency in Internal Medicine at Brigham and Women's Hospital, a chief residency in Internal Medicine at Faulkner Hospital, and a fellowship in Hematology/Oncology at Dana-Farber Cancer Institute/Partners CancerCare. She obtained a Master's in Public Health from the Harvard School of Public Health.
Dr. Mayer’s research focuses on the role of novel therapies in the treatment of advanced breast cancer. She has been published in numerous peer-reviewed publications including Nature, Journal of Biological Chemistry, Clinical Breast Cancer, Journal of Clinical Oncology, American Journal of Surgery, Annals of Oncology, and Clinical Cancer Research. She is the Associate Director of the Dana-Farber Partners CancerCare Hematology/Oncology Fellowship Program, and Co-Chair of the Dana-Farber Cancer Institute Clinical Faculty Council. Dr. Mayer is an active member of ASCO, ALLIANCE, as well as the Translational Breast Cancer Research Consortium. She is a graduate of the ASCO Leadership Development Program, has chaired the ASCO Cancer Education Committee Breast Track, and is a member of the ASCO Cancer Communications Committee.
Steven J. O'Day, MD is the Professor of Medical Oncology, Director of Immuno-Oncology, Director of Clinical Research of the Melanoma Medical Oncology Program at The John Wayne Cancer Institute at Providence St. John’s Health Center. He was most recently Director of the Los Angeles Skin Cancer Institute and Director of Clinical Research at The Beverly Hills Cancer Center. Prior to that, Dr. O’Day was Chief of Research and Director of the Melanoma Program at The Angeles Clinic and Research Institute in Los Angeles. He is a Clinical Associate Professor of Medicine at the University of Southern California (USC) Keck School of Medicine. He is a board certified medical oncologist.
Dr. O’Day’s medical training was at Johns Hopkins in Baltimore and the Dana Farber Cancer Institute in Boston. In 1994 Dr. O’Day came to Los Angeles to found the Medical Oncology Division of The John Wayne Cancer Institute in partnership with the world-class Surgical Oncology faculty and melanoma experts of The John Wayne Cancer Institute. More recently, he was a founding member of The Angeles Clinic and Research Institute in Santa Monica, California.
Dr. O’Day is recognized as one of the preeminent melanoma specialists in the world, and combines expert clinical care with teaching and leading clinical research. He lectures extensively, both nationally and internationally. He has been at the forefront of new drug development in melanoma over the last two decades. Dr. O’Day played a leadership role in the development of the breakthrough immune checkpoint inhibitor ipilimumab as well as the anti-PD1 antibodies pembrolizamab and nivolumab. In addition, he has participated in the development of the MAPK inhibitors vemurafinib, dabrafinib, and trametinib.
Dr. O’Day has been a principal investigator on over 100 clinical trials including several large, international phase III trials. He has published more than 200 manuscripts, abstracts, and reviews in prestigious journals such as The New England Journal of Medicine (NEJM), Journal of Clinical Oncology (JCO), Blood, Journal of American Medical Association (JAMA), Cancer, Lancet Oncology, and the Journal of the National Cancer Institute.
Dr. O’Day has served on the ASCO Education Committee for melanoma. In addition, he has served on the ASCO International Development and Education Award (IDEA) Working Group where he was a mentor for an IDEA grant recipient as well as an IDEA grant reviewer. Dr. O’Day recently completed a three-year term on the prestigious ASCO Cancer Communications Committee where he moderated ASCO press conferences, most notably the ASCO 2014 Immuno-Oncology Press Conference.
Olatoyosi Odenike, MD, is currently an Associate Professor of Hematology/Oncology in the Department of Medicine at the University of Chicago. She earned her medical degree from the University of Ibadan in Nigeria and completed her residency at the University of Illinois at Chicago, and fellowship in Hematology/Oncology at the University of Chicago.
An expert in the care of adults with leukemia, chronic myeloproliferative diseases and myelodysplastic syndromes, Dr. Odenike serves on the editorial board for the Blood Cancer Journal and Frontiers in Hematology-Oncology and as a reviewer for several medical journals. Additionally, she is a member of the Alliance Leukemia Committee, the International Working Group for Myelofibrosis Research and Treatment, the Molecular and Cellular Hematology NIH Study Section and currently serves on ASCO’s Grants Selection and Cancer Communications Committees.
Dr. Odenike has been listed in both Best Doctors of America and Marquis Who’s Who and is a recipient of the ASCO Career Development Award. The overall goal of her research is to improve treatment options for patients with myeloid neoplasms. She has published a number of original articles and has served as the principal investigator in several clinical trials. Additionally, Dr. Odenike frequently speaks around the country on advances in leukemia and myeloproliferative neoplasms.
Jyoti D. Patel, MD, is Associate Professor of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine and leader of the Aerodigestive Malignancy Group of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. Her clinical and research interests include lung cancer chemotherapy and lung cancer in women.
Charles J Ryan, MD, is Professor of Clinical Medicine and Urology at the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco (UCSF). He is the Leader of the Genitourinary Medical Oncology Program, overseeing the clinical research efforts of a group of genitourinary medical oncologists conducting clinical trials in prostate, kidney and bladder cancer. Within UCSF he is the Chair of the Genitourinary Oncology Clinical Research Site Committee and the Committee on Human Research (the UCSF IRB). Nationally, he serves as Co-Chair of the National Cancer Institute’s GU Steering Committee Prostate Cancer Task Force and is a member of the National Comprehensive Cancer Network (NCCN) Kidney/Testicular Cancer Guideline Panel, and the Leader of the Advanced Prostate Cancer Cadre in the Alliance for Clinical Trials in Oncology, an NCI sponsored cooperative group. Dr Ryan earned a bachelors degree from Marquette University and attended the University of Wisconsin Medical School. He trained in Internal Medicine at the University of Wisconsin Hospital and Clinics, where he also served as Chief Resident. He completed fellowship training in Medical Oncology at Memorial Sloan-Kettering Cancer Center and joined the faculty at UCSF in 2003.
His research focuses on novel therapy development in in castration resistant prostate cancer (CRPC) and has over 100 peer reviewed publications in this area. A major focus of his work has been the clinical development of CYP-17 inhibitors and related androgen receptor directed approaches to advanced disease.
Michael S. Sabel, MD, FACS, is the William W. Coon Collegiate Professor of Surgical Oncology in the Department of Surgery and the Chief of the Division of Surgical Oncology at the University of Michigan. He completed his undergraduate training at Pennsylvania State University and obtained his medical degree from Temple University School of Medicine in Philadelphia. His general surgery residency was performed at Rush-Presbyterian-St. Luke’s Medical Center in Chicago. Dr. Sabel completed an NIH-T32 research fellowship in tumor immunology and a surgical oncology fellowship at Roswell Park Cancer Institute in Buffalo, NY. Dr. Sabel joined the University of Michigan faculty in 2001. He has been listed in Best Doctors in America in Surgical Oncology every year since 2007 and has named as one of the U.S. News and World Report Top Doctors in Surgery since 2011.
Dr. Sabel’s clinical interests are in the area of surgical oncology, with special expertise in breast cancer and melanoma. Dr. Sabel’s research interests focus on the immune response to cancer cell death, particularly after cryoablation (freezing) of cancer, and he is an internationally recognized expert in the field of cryo-immunology. Dr. Sabel’s lab is also focused on the identification of prognostic and predictive markers in oncology, using both serum proteomic and tissue microarray approaches, to help guide surgical and adjuvant therapy.
In addition to his clinical and basic science interests, Dr. Sabel has strong clinical interests in the use of mobile technologies to improve patient-physician communication and improve outcomes. He is the creator of three present apps; UMSkinCheck for early melanoma detection, and BreastCancerAlly and MelanomaAlly, mobile patient navigator apps for patients requiring multidisciplinary cancer care.
Lidia Schapira, MD, is a medical oncologist at the Gillette Center for Breast Oncology at the Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard Medical School. She graduated from Dartmouth Medical School and trained at the Beth Israel Hospital and the Brigham and Women's Hospital. Dr. Schapira specializes in the care of women with breast cancer.
Dr. Schapira's research has focused on improving communication between patients and physicians and how best to meet the needs of patients and their families along the continuum of disease. She has developed innovative curriculum for postgraduate medical education and led workshops designed to improve the knowledge and skill set of clinicians. Dr. Schapira has also studied the barriers to communication and participation in cancer clinical trials. She has worked with professional societies and advocacy groups to improve awareness and bridge communication gaps that deter patients from participating in cancer clinical trials. In addition to research and clinical practice, Dr. Schapira is an active member of the Academy at Harvard Medical School and the Empathy and Relational Science Program at the Massachusetts General Hospital in Boston.
Dr. Schapira served on the Board of Directors of the American Psychosocial Oncology Society. In 2010 she received a "Statesman Award" from ASCO for her years of dedicated service to this professional society.
Lynn Mara Schuchter, MD, FASCO, is the University of Pennsylvania’s C. Willard Robinson Professor of Hematology/Oncology, Chief of the Hematology/Oncology Division and Program Leader for the Abramson Cancer Center’s National Cancer Institute approved and funded Melanoma Research Program. Her research has focused on the development of new treatments for patients with melanoma in studies that have focused on immunotherapy and targeted approaches. Dr. Schuchter has utilized her senior administrative, clinical, and investigative leadership strengths and experiences at the University of Pennsylvania to foster translational research. She has extensive experience in melanoma translational research, and thus serves as an important link between basic scientists and clinical investigators. She is a recognized expert in the field of melanoma and an experienced investigator in the development and conduct of melanoma clinical trials. She has been the principal investigator of numerous phase I, phase II, and phase III melanoma clinical trials. She is the immediate past chair of the scientific advisory committee and a member of the board of the Melanoma Research Foundation, a nationwide organization that is the largest advocate group for this disease. She is a recent past member of the American Society of Clinical Oncology (ASCO) Board of Directors, and current Chair of ASCO’s Cancer Research Committee. Dr. Schuchter has a strong commitment to and passion for mentorship and a long track record of success. She has a proven record of training physicians and scientists interested in both translational and clinical oncology research. She believes that careful mentoring is critical to the success of the next generation of cancer researchers which has been an essential component of her career. She serves as mentor for residents, fellows, and faculty and has particular interest in the mentorship of junior faculty.
Julie M. Vose, MD, MBA, FASCO, is the Neumann M. and Mildred E. Harris Professorial Chair and Chief of the Oncology/Hematology Division in the Department of Internal Medicine at the University of Nebraska Medical Center (UNMC). She is also the Associate Director of Clinical Research at the Fred and Pamela Buffett Cancer Center.
In addition to being ASCO President, Dr. Vose also serves on the Special Awards Selection, Nominating, and Scientific Program Committees. An ASCO member since 1991, Dr. Vose has served on the Board of Directors, Health Disparities Committee, Hematology-Oncology Task Force, Cancer.Net Advisory Panel and Editorial Board, and Journal of Clinical Oncology Editorial Board. She also served as Chair of the Cancer Education Committee and Publications Committee.
Dr. Vose was Co-Chair of the Lymphoma Steering Committee for the National Cancer Institute and has served on the U.S. Food and Drug Administration (FDA) Biologics Committee and the FDA Oncologic Drugs Advisory Committee (ODAC). She also served as Education Committee Chair for the American Society of Hematology and Education Committee Chair for the American Society of Bone Marrow Transplantation. In addition, Dr. Vose served as Journal Editor of Leukemia and Lymphoma, is on three additional editorial boards, and is a reviewer for 10 journals.
She received her undergraduate degree from South Dakota State University, her medical degree from the University of Nebraska Medical Center, and her MBA in health administration from the University of Colorado Business School. She completed her residency and was Chief Resident in internal medicine and her fellowship in Hematology/Oncology at the University of Nebraska Medical Center.